2-Tert-butyl-7-methylpyrrolo[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2-Tert-butyl-7-methylpyrrolo[2,3-d]pyrimidine
• 英文别名: 2-tert-butyl-7-methylpyrrolo[2,3-d]pyrimidine
• 化学式: C₁₁H₁₅N₃
• 分子量: 189.26
• InChiKey: NLEKBCNUSITNKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20150133427A1

  公开（公告）日：2015-05-14

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐和药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] INHIBITEUR DE PB2, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] PB2抑制剂及其制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2022007966A1

  公开（公告）日：2022-01-13

  涉及一种式（I）的化合物，其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐、共晶或前药，或含它们的药物组合物，及其作为PB2抑制剂在制备治疗相关疾病的药物中的用途，式（I）中各基团如说明书之定义。 Cy 1-L 1-Cy 2-L 2-Cy 3 （I）
• 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
  申请人：Shapiro Gideon

  公开号：US20180170935A1

  公开（公告）日：2018-06-21

  Disclosed are chemical entities of Formula (I), wherein R 1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
• TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS
  申请人：Rugen Holdings (Cayman) Limited

  公开号：US20210220365A1

  公开（公告）日：2021-07-22

  Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
• US8906900B2
  申请人：——

  公开号：US8906900B2

  公开（公告）日：2014-12-09